视频胶囊内镜用于小肠克罗恩病活动度纵向监测的效用:一项前瞻性研究
这项前瞻性多中心研究评估了小肠胶囊内镜(CE)对克罗恩病(CD)患者黏膜炎症的纵向评估价值。74例已知CD受试者在基线和6个月随访时接受回结肠镜和CE检查,回结肠镜SES-CD评分与CE的Lewis评分(P < .001,ρ = .59)及CECDEIS评分(P = .002,ρ = .48)相关,但三种内镜评分均与临床参数不相关。约85%受试者经CE发现近端小肠炎症,无CE相关不良事件,结论认为系列CE评估小肠CD可行且有效。
要点
- 回结肠镜SES-CD评分与CE的Lewis评分(P < .001,ρ = .59)及CECDEIS评分(P = .002,ρ = .48)相关。
- 三种内镜评分均与PGA、CDAI、HBI、C反应蛋白、红细胞沉降率或粪便钙卫蛋白不相关。
- 约85%受试者经CE发现近端小肠炎症,无CE相关不良事件。
核心结论
- CE与回结肠镜评分在纵向评估黏膜疾病活动度方面高度相关,但内镜评分与临床参数之间无相关性。
- 系列CE用于评估小肠CD可行且有效。
研究设计与样本
- 前瞻性多中心研究,已知CD受试者在基线和6个月随访时接受临床评估、回结肠镜和CE检查,CE前两个时间点均确认小肠通畅。
- 回结肠镜采用SES-CD评分,CE采用Lewis评分和CECDEIS评分;临床评分包括PGA、CDAI和HBI;实验室标志物包括C反应蛋白、粪便钙卫蛋白和红细胞沉降率。
- 共纳入74例受试者,其中53例(72%)完成了基线和6个月随访时的内镜操作。
主要发现
- 回结肠镜SES-CD评分与Lewis评分相关(P < .001,ρ = .59),与CECDEIS胶囊评分相关(P = .002,ρ = .48)。
- 三种内镜评分均与PGA、CDAI、HBI、C反应蛋白、红细胞沉降率或粪便钙卫蛋白不相关。
- 约85%受试者经CE发现近端小肠炎症。
- 无CE相关不良事件。
临床怎么用
- 原文结论认为系列CE用于评估小肠CD可行且有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: This prospective, multicenter study evaluated small-bowel capsule endoscopy (CE) for the longitudinal assessment of mucosal inflammation in subjects with Crohn's disease (CD). METHODS: Subjects with known CD underwent clinical evaluation with ileocolonoscopy and CE at baseline and 6-month follow-up. Small-bowel patency was confirmed before CE at both time points. The Simple Endoscopic Score for CD (SES-CD) was used for ileocolonoscopy, and the Lewis score and the CE CD Endoscopic Index of Severity (CECDEIS) were used for CE. Clinical scoring indices included the Physician Global Assessment (PGA), CD Activity Index (CDAI), and Harvey-Bradshaw Index (HBI). Laboratory markers including C-reactive protein, fecal calprotectin, and erythrocyte sedimentation rate were collected at baseline and follow-up. Correlation between endoscopic scores and clinical parameters were measured using Spearman tests. RESULTS: A total of 74 subjects were enrolled, of whom 53 (72%) completed endoscopic procedures at baseline and 6-month follow-up. The SES-CD ileocolonoscopy score correlated with the Lewis score (P < .001, ρ = .59) and CECDEIS capsule score (P = .002, ρ = .48). None of the 3 endoscopic scores correlated with PGA, CDAI, HBI, C-reactive protein, erythrocyte sedimentation rate, or fecal calprotectin. Approximately 85% of subjects had proximal small-bowel inflammation identified on CE. There were no CE-related adverse events. CONCLUSIONS: There was high correlation between CE and ileocolonoscopy scores for the assessment of mucosal disease activity over time; however, there were no correlations between endoscopic scores and clinical parameters. The use of serial CE for the assessment of small-bowel CD is feasible and valid. (Clinical trial registration number: NCT01942720.).
引用
- Melmed GY, Dubinsky MC, Rubin DT, et al. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc. 2018. PMID: 30086261. doi:10.1016/j.gie.2018.07.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。